DaVita Inc. (DVA) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Medical Care Facilities
Is DaVita Inc. a safe investment right now?
As of Aug 13, 2026, our estimated fair value (intrinsic value) for DaVita Inc. (DVA) stock is $166.53, versus a market price of $180.06 — Fairly Valued. Predicted EPS $12.81 x 13.0 Fair PE.
DaVita Inc.'s Altman Z-Score of 1.6 places it in the distress zone. Our fair value estimate is $166.53 (Fairly Valued). Moat rating: 3.7/5 stars.
Could DaVita Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 1.6 falls below the 1.8 distress threshold, indicating significant financial stress.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives DVA's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.0524 | 1.2 | 0.06 |
| B · Retained Earnings / Total Assets | RE / TA | -0.0188 | 1.4 | -0.03 |
| C · EBIT / Total Assets | EBIT / TA | 0.1102 | 3.3 | 0.36 |
| D · Market Cap / Total Liabilities | MCap / TL | 0.7038 | 0.6 | 0.42 |
| E · Revenue / Total Assets | Rev / TA | 0.7805 | 1.0 | 0.78 |
How has DVA's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 1.46 | Distress |
| 2023 | 1.6 | Distress |
| 2024 | 1.75 | Distress |
| 2025 | 1.6 | Distress |
Source: Calculated from DVA's latest 10-K filing on SEC EDGAR.
DaVita Inc. Fair Value & Intrinsic Value — What Is It Actually Worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $12.81 | Proprietary blend of reported actuals (2Q actual) + analyst consensus, weighted by α |
| Last Year EPS | $9.84 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $14.85 | 7 analysts consensus |
| Trailing P/E | 15.3x | Current market pricing |
| Fair P/E (β discount) | 13.0x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Growing | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $218.43 (7 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does DaVita Inc. have a durable competitive advantage?
Moat rating: 3.7/5.
What makes up DVA's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 4/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 4/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is DVA's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 13.7% | — |
| 2023 | 16.7% | Rising |
| 2024 | 20.9% | Rising |
| 2025 | 20.0% | Stable |
Source: ROIC calculated from SEC EDGAR filings.
Is DaVita Inc.'s dividend safe?
DaVita Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $13.6B | $12.8B | $11.6B | Rising |
| Net Income | $0.7B | $0.9B | $0.6B | Rising |
| Free Cash Flow | $1.3B | $1.5B | $1.0B | Rising |
| Gross Margin | 32.2% | 32.9% | 29.3% | Rising |
Recent events that affect our DVA analysis
DVA earnings report scheduled
Upcoming report. Consensus EPS estimate: $3.58. Revenue estimate: $3.51B. Our current Fair Value: $166.53 — a significant beat or miss could shift this estimate.
DVA analyst consensus: 38% bullish (3 of 8 analysts)
0 Strong Buy, 3 Buy, 4 Hold, 0 Sell, 1 Strong Sell. Consensus target: $218.43 (21.3% upside). Compare with our independent Fair Value: $166.53.
DVA beat EPS estimates by 3.5%
Reported EPS: $4.02 vs estimate $3.88. Earnings strength supports our Fair Value of $166.53 (7.5% below current price).
DVA filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA beat EPS estimates by 23.2%
Reported EPS: $2.87 vs estimate $2.33. Earnings strength supports our Fair Value of $166.53 (7.5% below current price).
DVA filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
DVA beat EPS estimates by 6.5%
Reported EPS: $3.40 vs estimate $3.19. Earnings strength supports our Fair Value of $166.53 (7.5% below current price).
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA missed EPS estimates by 20.9%
Reported EPS: $2.51 vs estimate $3.17. Our Fair Value of $166.53 may face downward pressure if the trend continues.
DVA filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA beat EPS estimates by 7.3%
Reported EPS: $2.95 vs estimate $2.75. Earnings strength supports our Fair Value of $166.53 (7.5% below current price).
DVA filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA missed EPS estimates by 0.9%
Reported EPS: $2.00 vs estimate $2.02. Our Fair Value of $166.53 may face downward pressure if the trend continues.
DVA filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
DVA beat EPS estimates by 5.4%
Reported EPS: $2.24 vs estimate $2.13. Earnings strength supports our Fair Value of $166.53 (7.5% below current price).
DVA filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
DVA filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about DaVita Inc.
What is DaVita Inc. stock price today?
DaVita Inc. (DVA) stock price is $180.06 as of the latest market close, traded on the NYSE exchange.
What does DaVita Inc. do?
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. It operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
What is DaVita Inc. market cap?
DaVita Inc. has a market capitalization of $11.49B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is DVA in?
DaVita Inc. operates in the Healthcare sector, specifically within the Medical Care Facilities industry. It trades on the NYSE under the ticker symbol DVA.
Is DVA stock overvalued or undervalued?
Based on our valuation model, DaVita Inc. trades 8.1% above our fair value estimate — potentially overvalued.
- FairValueLabs Fair Value: $166.53
- Current Price: $180.06
- Valuation Zone: Fairly Valued
What is DVA stock forecast and analyst target price?
Based on 7 Wall Street analysts, the consensus price target for DaVita Inc. is $218.43, implying upside of 21.3% from the current price.
- Analyst High Target: $270.00
- Analyst Low Target: $165.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is DaVita Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for DaVita Inc.:
- Revenue growth (current year est.): 3.7%
- EPS growth (current year est.): 37.7%
- Revenue growth (next year est.): 3.2%
- EPS growth (next year est.): 14.6%
What are DaVita Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $13.6B | Rising |
| Net Income | $0.7B | Rising |
| Free Cash Flow | $1.3B | Rising |
| Gross Margin | 32.2% | Rising |
What is DVA's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 15.2x
- Forward P/E (next 12 months est.): 10.6x
- FairValueLabs Fair P/E: 13.0x
How volatile is DVA stock?
DaVita Inc. has a beta of 0.87, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does DaVita Inc. have?
DaVita Inc.'s balance sheet shows:
- Total Cash: $688.9M
- Total Debt: $13.41B
- Net Cash Position: $-12.72B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is DaVita Inc.'s free cash flow?
DaVita Inc. generated $1.04B in trailing twelve-month free cash flow (from $2.19B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does DaVita Inc. pay a dividend?
DaVita Inc. does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is DaVita Inc. at risk of going bankrupt?
DaVita Inc.'s Altman Z-Score is 1.60, placing it in the distress zone (below 1.8) — elevated bankruptcy risk. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does DaVita Inc. have a durable competitive advantage?
DaVita Inc. scores 3.7/5 stars (Solid moat · eroding) in our moat analysis:
- ROIC Stability: 4/5
- Gross Margin Trend: 4/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is DVA's return on equity (ROE)?
DaVita Inc.'s return on equity is 88.5%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy DVA stock?
DVA shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol DVA
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is DVA a value stock or speculative?
FairValueLabs classifies DaVita Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of DaVita Inc.?
The current CEO of DaVita Inc. is Mr. Javier J. Rodriguez.
What is DVA's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $11.81
- Forward EPS (next 12 months est.): $17.02
- Analyst consensus EPS (this year): $14.85
- Analyst consensus EPS (next year): $17.02
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Aug 13, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
DVA analysis methodology: How we calculate fair value, Z-Scores, and moat ratings